Cellectis (LTS:0WA2) Accumulated Depreciation : €-90.50 Mil (As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Cellectis Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Cellectis's quarterly accumulated depreciation increased from Sep. 2024 (€-80.98 Mil) to Dec. 2024 (€-87.27 Mil) and increased from Dec. 2024 (€-87.27 Mil) to Mar. 2025 (€-90.50 Mil).

Cellectis's annual accumulated depreciation increased from Dec. 2022 (€-52.60 Mil) to Dec. 2023 (€-69.16 Mil) and increased from Dec. 2023 (€-69.16 Mil) to Dec. 2024 (€-87.27 Mil).

Cellectis Accumulated Depreciation Historical Data

The historical data trend for Cellectis's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Accumulated Depreciation Chart

Cellectis Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accumulated Depreciation

Get a 7-Day Free Trial

-27.06

-41.75

-52.60

-69.16

-87.27

Cellectis Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accumulated Depreciation	Get a 7-Day Free Trial															-72.80	-77.51	-80.98	-87.27	-90.50

Cellectis Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Cellectis Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Cellectis's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Cellectis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

CMVLF:USA CLLS:USA ALCLS:France ZVA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Cellectis Headlines

No Headlines